9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Canakinumab, a monoclonal antibody targeting interleukin (IL)-1β, reduces rates of recurrent cardiovascular events without lowering lipids. It is uncertain, however, to what extent these beneficial cardiovascular outcomes are mediated through interleukin-6 (IL-6) signalling, an issue with substantial pathophysiologic consequences and therapeutic implications.

          Related collections

          Author and article information

          Journal
          European Heart Journal
          Oxford University Press (OUP)
          0195-668X
          1522-9645
          October 07 2018
          October 07 2018
          August 26 2018
          October 07 2018
          October 07 2018
          August 26 2018
          : 39
          : 38
          : 3499-3507
          Affiliations
          [1 ]Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA, USA
          [2 ]Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA
          [3 ]Novartis Pharmaceutical Corporation, One Health Plaza, East Hanover, NJ, USA and Basel, Switzerland
          [4 ]Baylor College of Medicine, Alkek Tower, Houston, TX, USA
          [5 ]Federal University of Sao Paulo, Via Clementino, Sao Paulo SP, Brazil
          [6 ]Deutsches Herzzentrum München, Technische Universität München, Munich Heart Alliance, Lazarettstraße 36, München, Germany
          [7 ]Department of Cardiovascular Medicine, Tohoku University Hospital, Seiryo-machi, Aoba-ku, Sendai, Japan
          Article
          10.1093/eurheartj/ehy310
          30165610
          a95c3778-bc21-4725-898b-fde2a33c755c
          © 2018

          https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

          History

          Comments

          Comment on this article